The quick answer: tesamorelin is not an established appetite treatment. It stimulates growth hormone, and its pivotal trials measured visceral fat reduction in adults with HIV-associated lipodystrophy. The label calls it weight neutral [2].
Does tesamorelin change appetite?
The Egrifta label lists no change in appetite, hunger or food intake in its warnings, side effects or clinical studies [2]. The pivotal trials didn't use appetite as an outcome either [3].
A small tesamorelin trial in older adults with HIV recorded one appetite-loss event in each group. Those few reports do not establish whether the drug changes appetite [6].
So if you've read that tesamorelin "curbs cravings" or "makes you hungry", neither claim has a study behind it.
How it reduces belly fat
Tesamorelin raises growth hormone, which the label describes as lipolytic, meaning it breaks down stored fat [2]. In trials, the drop showed up mainly in visceral fat.
In the pivotal trial of 412 adults with HIV, visceral fat fell 15.2% on daily tesamorelin and rose 5.0% on placebo over 26 weeks [3]. A pooled analysis of two phase 3 trials, 806 people in all, put the treatment effect at −15.4% [4].
| Measure | Tesamorelin | Placebo | Source |
|---|---|---|---|
| Visceral fat, 26 weeks | −15.2% | +5.0% | Falutz 2007 [3] |
| Visceral fat, treatment effect (pooled) | −15.4% | Comparison group | Falutz 2010 [4] |
| Fat under the skin of the belly, treatment effect | −0.6% (not significant) | Comparison group | Falutz 2010 [4] |
| Triglycerides | −50 mg/dL | +9 mg/dL | Falutz 2007 [3] |
| Body weight | "Weight neutral" | Not stated | Egrifta SV label [2] |
| Appetite | Not reported | Not reported | Egrifta SV label [2] |
Why deep belly fat is the target
Visceral fat builds up in many people on long-term HIV treatment, and it's linked to higher heart risk [3]. That's the problem the drug was built to fix.
Alongside the fat drop, the pivotal trial saw better blood fats. Triglycerides fell, and the ratio of total to HDL cholesterol dropped 0.31 on tesamorelin while it rose 0.21 on placebo [3]. In the pooled trials, people also reported less distress about how their belly looked [4].
Heads up on the limits. The label says long-term heart safety hasn't been established. It also tells prescribers to weigh whether to continue in people whose visceral fat doesn't go down [2].
Why your weight may not change
Visceral fat fell while fat under the skin and total weight stayed about the same. That's why the label calls the drug weight neutral [2].
EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect.[2]
Growth hormone also builds lean tissue, so some of the fat lost can be offset on the scale. For what the trials show on that side, see whether tesamorelin builds muscle. For when changes show up, see how long tesamorelin takes to work.
Does it burn fat in people without HIV?
The pivotal fat-reduction data come from adults with HIV-associated lipodystrophy [3]. A separate cognition trial included healthy older adults and measured body composition, so it would be inaccurate to say no study has tested adults without HIV. These studies do not establish a general weight-loss indication [1].
One off-label trial looked at liver fat, again in people with HIV. In 61 adults with fatty liver disease, tesamorelin cut liver fat by 37% relative to baseline compared with placebo over 12 months [5]. It's a single, small trial, and its authors called for longer studies.
Fitness and anti-aging pages often stretch the HIV results to everyone. The trials don't support that leap. People with HIV lipodystrophy have an unusual fat pattern, and a healthy adult may respond differently, or not at all.
What the label warns about for metabolism
Tesamorelin can worsen blood sugar. By week 26, 5% of people on it vs 1% on placebo had an HbA1c of 6.5% or higher, the diabetes range [2].
The label asks prescribers to check glucose before starting and periodically after. It also asks them to monitor IGF-1, the hormone growth hormone raises, and consider stopping if it stays very high [2]. The pivotal trial on its own found no significant glucose differences [3], so the label's numbers come from its clinical trials as a whole.
Hormone questions come up a lot with this drug. See whether tesamorelin raises testosterone.
If belly fat or weight is your goal
Approved weight-management drugs act on appetite directly and carry their own label limits. Tirzepatide is one; see what tirzepatide is for how it works.
| What to compare | Tesamorelin (Egrifta SV) | Tirzepatide (Zepbound) |
|---|---|---|
| How it works | Raises your own growth hormone, which frees stored fat | Acts on GIP and GLP-1 receptors, including in brain areas that regulate appetite |
| Effect on eating | None listed | "Decreases calorie intake", likely through appetite |
| Effect on weight | "Weight neutral" | Lowers body weight, with more fat lost than lean |
| Labeled use | Excess belly fat in adults with HIV-associated lipodystrophy | Chronic weight management; sleep apnea in adults with obesity |
The table isn't a head-to-head. The two drugs were never compared in a trial, and they're labeled for different people.
Tesamorelin is FDA-approved as Egrifta, for HIV-associated belly fat, and since March 2020 it can't be compounded [8]. Read tesamorelin's legal status before you go further, or start with the metabolic shortlist.